LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.
Eyecelerator Presenting Company Showcase – OKYO Pharma Presentation Details
Date: Thursday, April 4, 2024
Time: 1:00 – 2:30PM ET
Location: Omni Boston Hotel at the Seaport – Level 2
Ensemble Ballroom C, Breakout 1
Presenter: Gary Jacob, PhD, Chief Executive Officer
About Eyecelerator
Eyecelerator is a partnership between the American Academy of Ophthalmology and ASCRS to accelerate ophthalmic innovation through next-generation business conferences. Held the Thursday before each partner society's annual meeting, Eyecelerator spurs innovation by connecting the scientific talent and entrepreneurs advancing eye care with mission-driven investors and business partners who support their success. Eyecelerator conferences provide a full day of KOL-driven programs highlighting industry advancements, investment trends, and innovative new products disrupting eye care. The conferences also provide valuable opportunities to network and explore new market potentials and the occasion for dozens of companies to present their novel clinical treatments and emerging technologies that are shaping the future of ophthalmology.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
